Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
GlobalData on MSN9h
Boehringer Ingelheim announces Phase III schizophrenia failuresThe company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...
As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
The $45-per-share agreement gives AbbVie a pipeline of CNS drugs headed by emraclidine (formerly CVL-231), a drug for schizophrenia with a new mechanism of action that could offer reduced side ...
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback